Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Increased Intracranial Pressure l: Introduction

Increased Intracranial Pressure l: Introduction

Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component...

Increased Intracranial Pressure ll: Pathophysiology

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Multicenter Training and Interrater Reliability Study of the BASED Score for Infantile Epileptic Spasms Syndrome.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2025

Same author

A Multicenter Training and Interrater Reliability Study of the BASED Score for Infantile Epileptic Spasms Syndrome.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2024

Same author

Increasing Provider Utilization of a Seizure Action Plan in the Outpatient Setting.

Pediatrics·2024

Same author

Natural History of Neuronal Ceroid Lipofuscinosis Type 6, Late Infantile Disease.

Pediatric neurology·2024

Same author

Persistent Elevation of Opening Pressure Despite Treatment and Symptom Resolution in Pediatric Intracranial Hypertension.

Pediatric neurology·2024

Same author

Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.

The Lancet. Neurology·2023

Search research articles

Related Experiment Video

Updated: May 6, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Advancements in pediatric headache.

Richard N Miller¹, Monica E Kim¹, Muhammed Talha Gunduz¹

¹Department of Pediatrics.

Current Opinion in Pediatrics

|October 14, 2024

Summary

Recent advancements in pediatric headache include updated diagnostic criteria and effective treatments. Therapies like onabotulinum toxin A and intranasal sumatriptan show promise for managing pediatric headache syndromes.

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

Related Experiment Videos

Last Updated: May 6, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

Area of Science:

Pediatric Neurology
Headache Medicine
Clinical Research

Background:

Primary headache disorders in children require updated understanding.
International Classification of Headache Disorders 3rd edition (ICHD-3) criteria are being refined.
Pediatric headache management necessitates evidence-based therapeutic updates.

Purpose of the Study:

To review recent advancements in pediatric headache.
To update clinicians on current pediatric headache research and treatment outcomes.

Main Methods:

Review of recent studies comparing pediatric headache symptomatology with ICHD-3 criteria.
Analysis of treatment outcomes for various pediatric headache interventions.
Evaluation of novel therapeutic approaches including pharmacologic and toxin-based therapies.

Main Results:

Primary stabbing headache duration may exceed previous estimates.
Persistent posttraumatic and new daily persistent headaches share features with migraine.
Lifestyle improvements showed no direct correlation with headache outcome, though overall improvement was noted.
Onabotulinum toxin A and incobotulinum toxin A injections demonstrated significant headache score reduction with minimal side effects.
Intranasal sumatriptan proved effective in reducing pain scores in emergency settings, potentially lowering costs and length of stay.

Conclusions:

Pediatric headache syndromes exhibit evolving symptomatology and duration characteristics.
Onabotulinum toxin A and incobotulinum toxin A injections are well-tolerated and effective.
Emergency department administration of intranasal sumatriptan is a viable and effective treatment option for pediatric headache.